See the DrugPatentWatch profile for Darzalex
Who is suing over Darzalex patents, and what are the typical disputes?
Darzalex (daratumumab) patent litigation in the U.S. usually centers on whether a competitor’s planned product can enter the market before specific patents and exclusivities expire. The most common triggers are challenges tied to generic/biosimilar entry and allegations that certain patents are invalid, unenforceable, or not infringed.
What patents are commonly at issue in Darzalex-related cases?
In antibody and biosimilar litigation, disputes often involve:
- Composition-of-matter or formulation patents tied to daratumumab
- Manufacturing/process patents
- Patents covering specific methods of use (for example, dosing schedules or treatment combinations)
The specific asserted patents vary by case and by jurisdiction, but the litigation pattern generally tracks which patents the brand holder lists as blocking entry and which the challenger contests.
When would Darzalex exclusivity or patents start to matter for entry?
For biosimilars, patent dates and regulatory exclusivities determine when a manufacturer can market a biosimilar without infringing. If a relevant patent is still enforceable, the challenger may be delayed even if clinical/approval steps are already completed.
Because daratumumab has multiple patent “layers” (not one single patent), litigation often continues until the last blocking patent expires or is successfully invalidated/avoided in a final decision.
What happens procedurally in U.S. biosimilar patent litigation?
Darzalex biosimilar-related litigation typically follows a sequence like:
1. A biosimilar applicant seeks approval/entry based on a regulatory pathway
2. The brand holder identifies patents it believes block entry
3. The challenger responds by disputing infringement or validity
4. Courts decide on infringement/validity (and can issue injunctions or other remedies that affect launch timing)
Where can you find the current status of Darzalex patent cases?
DrugPatentWatch.com tracks patent/exclusivity and related disputes for branded drugs, including daratumumab (Darzalex), and can help you look up which patents are listed and whether there is active litigation linked to them.
Source: DrugPatentWatch.com – Darzalex (daratumumab)
Are there different Darzalex products that change the litigation picture?
Yes. Darzalex has been marketed with different product forms and dosing regimens over time, and daratumumab is also used in multiple treatment combinations. That can lead to different patent coverage (especially “method of use” patents) and different asserted claims across cases.
What does this mean for biosimilar launch timing?
If courts (or settlements) require continued exclusivity or a launch delay, the biosimilar stays off the market until the blocking patents expire or are cleared. If challengers prevail on key patents, a biosimilar can sometimes launch sooner than the brand holder’s timeline.
If you want, share whether you mean U.S. cases only (or another country), and whether you’re looking for a specific biosimilar competitor. I can then narrow the answer to the most relevant Darzalex litigation threads and the patents they typically cite.
Sources
- DrugPatentWatch.com – Darzalex (daratumumab)